Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity
Zomedica Corp. (ZOMDF) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Zomedica Announces Record Second Quarter Revenue of $9.5 Million, Up 37% Year-Over-Year, Net Loss Reduced 49%, with $44.1 Million in Liquidity Zomedica surpasses $9 million in second quarter revenue for the first time while extending its record of consecutive year-ov
How this was made
The 30-second read
Why it matters
The filing discloses a set of operating KPIs investors typically use to reassess growth trajectory and cash runway: record quarterly revenue, gross margin level, operating expense reduction, and improved quarterly cash burn.
Market read
For traders, the actionable items are the hard 2Q26 numbers: $9.5M revenue (+37% YoY), 64% gross margin, operating expenses down 20%, and cash burn down 38% to $3.4M.
What to watch
The excerpt does not include full balance-sheet liquidity details, debt/financing plans, or forward guidance; traders may need the full 10-Q to assess sustainability of cash burn improvements.
Background
This is an SEC Form 8-K with Exhibit 99.1 reporting Zomedica’s consolidated financial results for the three and six months ended June 30, 2026.
Ticker impact
Zomedica reported 2Q26 revenue of $9.5M, up 37% YoY, plus reduced cash burn to $3.4M, in an SEC 8-K results filing.
Near-term upside bias on any market reaction to the revenue and cash-burn improvements, with volatility likely given OTC liquidity and ongoing losses.
The filing provides multiple concrete operating metrics (revenue growth, gross margin, operating expense decline, cash burn improvement) that can re-rate near-term fundamentals, though it does not include guidance or balance-sheet detail in the provided excerpt.
Market effects
Animal health diagnostics and point-of-care device peers may see read-across interest if investors rotate toward improving cash efficiency.
Limited, primarily affects US OTC animal health sentiment rather than a broad regional macro theme.
International expansion and partnerships are mentioned, but the excerpt does not quantify global demand beyond company-level growth rates.
Counterpoint
Revenue growth may be partially offset by margin pressure from ramping new products, and the company still reports a net loss, so the quality of earnings remains uncertain.
Key entities
- companyZomedica Corp.
OTC-listed animal health company reporting 2Q26 results and liquidity/cash burn improvements in an 8-K.
- partnerBoehringer Ingelheim Animal Health
Referenced as a collaboration supporting Diagnostics segment assays for the equine market.
